Denali Therapeutics Total Assets 2016-2024 | DNLI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Denali Therapeutics total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Denali Therapeutics total assets from 2016 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$155.8B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$116B
Gilead Sciences (GILD)	$111.9B
CSL (CSLLY)	$86.5B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.8B
Argenex SE (ARGX)	$35.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$25.9B
Biogen (BIIB)	$23B
Illumina (ILMN)	$21.7B
BeiGene (BGNE)	$18.9B
Moderna (MRNA)	$14.7B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.5B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.1B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$11B
Sarepta Therapeutics (SRPT)	$10.6B
Exelixis (EXEL)	$9.9B
Exact Sciences (EXAS)	$9.8B
QIAGEN (QGEN)	$9.7B
Revolution Medicines (RVMD)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.9B
Ascendis Pharma (ASND)	$7.4B